NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
Effectiveness and duration of intramuscular antimotion sickness medicationsMotion sickness inhibits gastric motility, making the oral route ineffective for medications. The intramuscular route is an effective alternative. The rotating chair was used to produce the M 111 level of motion sickness on the Graybiel Symptom Scale. The intramuscular medications given 30 minutes before rotation were compared with placebo (saline, 1 mL) for effectiveness and duration in increasing the number of tolerated head movements. Average placebo number of head movements was 294. Promethazine 25 mg increased head movements by 78% (P < .05), with a duration of 12 hours. Scopolamine 0.2 mg increased head movements by 91% (P < .05), with a duration of 4 hours. The effect of caffeine 250 mg and ephedrine 25 mg was not significant. When combined with scopolamine, ephedrine produced an 32% additive effect. Scopolamine 0.08 mg, 0.1 mg, and 0.2 mg and also promethazine 12.5 mg and 25 mg were significant (P < .05). Promethazine appears to be the drug of choice for intramuscular use because of a longer duration and a high level of effectiveness. Scopolamine was of high effectiveness, but had a duration of 4 hours. It was eight times as potent by the intramuscular as by the oral route.
Document ID
20050000573
Acquisition Source
Legacy CDMS
Document Type
Reprint (Version printed in journal)
Authors
Wood, C. D.
(Louisiana State University Medical Center Shreveport 71130)
Stewart, J. J.
Wood, M. J.
Mims, M.
Date Acquired
August 22, 2013
Publication Date
November 1, 1992
Publication Information
Publication: Journal of clinical pharmacology
Volume: 32
Issue: 11
ISSN: 0091-2700
Subject Category
Aerospace Medicine
Distribution Limits
Public
Copyright
Other
Keywords
Non-NASA Center
Controlled Clinical Trial
Clinical Trial
NASA Discipline Neuroscience

Available Downloads

There are no available downloads for this record.
No Preview Available